CN104173295B - 林可霉素缓释颗粒 - Google Patents
林可霉素缓释颗粒 Download PDFInfo
- Publication number
- CN104173295B CN104173295B CN201410457772.8A CN201410457772A CN104173295B CN 104173295 B CN104173295 B CN 104173295B CN 201410457772 A CN201410457772 A CN 201410457772A CN 104173295 B CN104173295 B CN 104173295B
- Authority
- CN
- China
- Prior art keywords
- lincomycin
- parts
- clathrate
- slow
- cyclodextrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 title claims abstract description 93
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 title claims abstract description 93
- 229960005287 lincomycin Drugs 0.000 title claims abstract description 93
- 239000008187 granular material Substances 0.000 title abstract description 15
- 229920000858 Cyclodextrin Polymers 0.000 claims description 23
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims description 22
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 22
- 239000000463 material Substances 0.000 claims description 14
- 238000013268 sustained release Methods 0.000 claims description 14
- 239000012730 sustained-release form Substances 0.000 claims description 14
- 238000009472 formulation Methods 0.000 claims description 13
- -1 Chemical compound 0.000 claims description 4
- 229960003454 tamoxifen citrate Drugs 0.000 abstract 1
- FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 abstract 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 26
- 238000002360 preparation method Methods 0.000 description 21
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 18
- 230000000052 comparative effect Effects 0.000 description 18
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 13
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 13
- 239000008101 lactose Substances 0.000 description 13
- 235000019359 magnesium stearate Nutrition 0.000 description 13
- 229940085605 saccharin sodium Drugs 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 239000002671 adjuvant Substances 0.000 description 10
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 10
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 10
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 10
- 229960003943 hypromellose Drugs 0.000 description 10
- 229940075507 glyceryl monostearate Drugs 0.000 description 9
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 8
- 238000004090 dissolution Methods 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000001856 Ethyl cellulose Substances 0.000 description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 235000019325 ethyl cellulose Nutrition 0.000 description 3
- 229920001249 ethyl cellulose Polymers 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 2
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 238000007922 dissolution test Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000010316 high energy milling Methods 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012982 microporous membrane Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 2
- 208000031729 Bacteremia Diseases 0.000 description 1
- 206010061695 Biliary tract infection Diseases 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 208000033571 alveolar capillary dysplasia with misalignment of pulmonary veins Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000003167 cholangitis Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000013521 mastic Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 208000004594 persistent fetal circulation syndrome Diseases 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- RYVMUASDIZQXAA-UHFFFAOYSA-N pyranoside Natural products O1C2(OCC(C)C(OC3C(C(O)C(O)C(CO)O3)O)C2)C(C)C(C2(CCC3C4(C)CC5O)C)C1CC2C3CC=C4CC5OC(C(C1O)O)OC(CO)C1OC(C1OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OCC(O)C(O)C1O RYVMUASDIZQXAA-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
林可霉素包合物 | 50份 |
乳糖 | 190份 |
硬脂酸镁 | 4份 |
糖精钠 | 4份 |
羟丙甲纤维素 | 70份 |
单硬脂酸甘油酯 | 30份 |
聚氯乙烯 | 85份 |
包合材料 | 稳定性 | 包合率 |
γ-环糊精 | 好 | 98% |
α-环糊精 | 一般 | 83% |
β-环糊精 | 一般 | 82% |
羟基β-环糊精 | 一般 | 78% |
羟丙基β-环糊精 | 一般 | 80% |
林可霉素包合物 | 50份 |
乳糖 | 190份 |
硬脂酸镁 | 4份 |
糖精钠 | 4份 |
羟丙甲纤维素 | 70份 |
单硬脂酸甘油酯 | 30份 |
聚氯乙烯 | 85份 |
林可霉素包合物 | 50份 |
乳糖 | 190份 |
硬脂酸镁 | 4份 |
糖精钠 | 4份 |
羟丙甲纤维素 | 70份 |
单硬脂酸甘油酯 | 30份 |
聚氯乙烯 | 85份 |
林可霉素包合物 | 50份 |
乳糖 | 190份 |
硬脂酸镁 | 4份 |
糖精钠 | 4份 |
羟丙甲纤维素 | 185份 |
林可霉素包合物 | 50份 |
乳糖 | 190份 |
硬脂酸镁 | 4份 |
糖精钠 | 4份 |
单硬脂酸甘油酯 | 185份 |
林可霉素包合物 | 50份 |
乳糖 | 190份 |
硬脂酸镁 | 4份 |
糖精钠 | 4份 |
聚氯乙烯 | 185份 |
林可霉素包合物 | 50份 |
乳糖 | 190份 |
硬脂酸镁 | 4份 |
糖精钠 | 4份 |
乙基纤维素 | 185份 |
林可霉素包合物 | 50份 |
乳糖 | 190份 |
硬脂酸镁 | 4份 |
糖精钠 | 4份 |
羟丙甲纤维素 | 100份 |
单硬脂酸甘油酯 | 85份 |
林可霉素包合物 | 50份 |
乳糖 | 190份 |
硬脂酸镁 | 4份 |
糖精钠 | 4份 |
单硬脂酸甘油酯 | 100份 |
聚氯乙烯 | 85份 |
林可霉素包合物 | 50份 |
乳糖 | 190份 |
硬脂酸镁 | 4份 |
糖精钠 | 4份 |
羟丙甲纤维素 | 100份 |
乙基纤维素 | 85份 |
林可霉素包合物 | 50份 |
乳糖 | 190份 |
硬脂酸镁 | 4份 |
糖精钠 | 4份 |
羧甲基纤维素钠 | 100份 |
乙基纤维素 | 85份 |
林可霉素包合物 | 50份 |
乳糖 | 190份 |
硬脂酸镁 | 4份 |
糖精钠 | 4份 |
羟丙甲纤维素 | 50份 |
单硬脂酸甘油酯 | 80份 |
聚氯乙烯 | 55份 |
林可霉素 | 70份 |
乳糖 | 150份 |
硬脂酸镁 | 4份 |
糖精钠 | 4份 |
聚维酮 | 40份 |
卡波普 | 50份 |
聚甲基丙烯酸酯 | 50份 |
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410457772.8A CN104173295B (zh) | 2014-09-10 | 2014-09-10 | 林可霉素缓释颗粒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410457772.8A CN104173295B (zh) | 2014-09-10 | 2014-09-10 | 林可霉素缓释颗粒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104173295A CN104173295A (zh) | 2014-12-03 |
CN104173295B true CN104173295B (zh) | 2016-08-31 |
Family
ID=51954828
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410457772.8A Active CN104173295B (zh) | 2014-09-10 | 2014-09-10 | 林可霉素缓释颗粒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104173295B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105796505B (zh) * | 2016-03-18 | 2018-10-16 | 齐齐哈尔大学 | 一种林可霉素羧甲基壳聚糖-明胶复合微球及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002032459A2 (en) * | 2000-10-17 | 2002-04-25 | Massachusetts Institute Of Technology | Method of increasing the efficacy of antibiotics by complexing with cyclodextrins |
CN101380292A (zh) * | 2006-08-28 | 2009-03-11 | 孔庆忠 | 一种缓释注射剂及其制备方法和应用 |
CN103142500A (zh) * | 2013-03-21 | 2013-06-12 | 青岛正大海尔制药有限公司 | 一种依托泊苷缓释颗粒 |
-
2014
- 2014-09-10 CN CN201410457772.8A patent/CN104173295B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002032459A2 (en) * | 2000-10-17 | 2002-04-25 | Massachusetts Institute Of Technology | Method of increasing the efficacy of antibiotics by complexing with cyclodextrins |
CN101380292A (zh) * | 2006-08-28 | 2009-03-11 | 孔庆忠 | 一种缓释注射剂及其制备方法和应用 |
CN103142500A (zh) * | 2013-03-21 | 2013-06-12 | 青岛正大海尔制药有限公司 | 一种依托泊苷缓释颗粒 |
Also Published As
Publication number | Publication date |
---|---|
CN104173295A (zh) | 2014-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106924208A (zh) | 一种复方达格列净二甲双胍缓释片及其制备方法 | |
Zhang et al. | A sensitive and rapid radiolabelling method for the in vivo pharmacokinetic study of lentinan | |
CN102885777A (zh) | 高效氟苯尼考粉剂组合物及其制备方法 | |
CN102349915B (zh) | 一种氨酚咖敏维c制剂及其制备方法 | |
CN104173295B (zh) | 林可霉素缓释颗粒 | |
CN103610658A (zh) | 一种免疫调节剂缓释剂及其制备方法 | |
CN103251569B (zh) | 卡培他滨片组合物及其制备方法 | |
CN104650034A (zh) | 一种稳定的阿西替尼化合物 | |
CN104173304B (zh) | 林可霉素分散片 | |
CN101912407B (zh) | 一种减肥降脂组合物 | |
JP2017530162A (ja) | A−ノル−5αアンドロスタン化合物の経口投与製剤 | |
CN102274162A (zh) | 一种含有难溶性药物和亲水凝胶材料的固体组合物及其制备方法 | |
CN105193749A (zh) | 一种治疗泌尿外科类疾病的药物他达拉非组合物片剂 | |
CN103142500B (zh) | 一种依托泊苷缓释颗粒 | |
CN103142533B (zh) | 一种依托泊苷肠溶片 | |
CN104173314B (zh) | 妥布霉素肠溶片 | |
CN103142530B (zh) | 一种依托泊苷缓释片 | |
CN103142522B (zh) | 一种依托泊苷片剂 | |
CN105055353B (zh) | 一种恩替卡韦片及其制备方法 | |
CN103349647B (zh) | 枸橼酸他莫昔芬缓释颗粒 | |
CN102335153A (zh) | 一种阿魏酸哌嗪缓释片及其制备方法 | |
CN109700778B (zh) | 一种盐酸西那卡塞速释制剂及其制备方法 | |
CN103349650B (zh) | 枸橼酸他莫昔芬缓释片剂 | |
CN103393616B (zh) | 枸橼酸他莫昔芬片 | |
CN106727371A (zh) | 盐酸多奈哌齐药物组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
CB03 | Change of inventor or designer information |
Inventor after: Li Shulan Inventor before: Huang Xiangbin Inventor before: Li Zhizheng Inventor before: Zhou Dai Inventor before: Xie Panjin |
|
COR | Change of bibliographic data | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160801 Address after: 266000 Shandong province Qingdao city Licang District Road No. 1020 Laoshan two unit 302 Applicant after: Li Shulan Address before: The new Chengdu high tech Zone of Sichuan province 611731 City Road No. 22 Applicant before: Sichuan Xingkerong Pharmaceutical Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP02 | Change in the address of a patent holder |
Address after: 516800 industrial transfer Industrial Park No. three, Longmen County, Huizhou City, Guangdong Province, No. 1 Patentee after: Li Shulan Address before: 266000 Shandong province Qingdao city Licang District Road No. 1020 Laoshan two unit 302 Patentee before: Li Shulan |
|
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: 210000 Phoenix Plaza, No. 1 Hunan Road, Gulou District, Nanjing City, Jiangsu Province Patentee after: Li Shulan Address before: 516800 No. 1 Industrial Road three, industrial transfer industrial park, Longmen, Huizhou, Guangdong Patentee before: Li Shulan |
|
CP02 | Change in the address of a patent holder | ||
TR01 | Transfer of patent right |
Effective date of registration: 20191105 Address after: 221000 no.3-1, industrial park, suyangshan Town, Pizhou City, Xuzhou City, Jiangsu Province Patentee after: Pizhou SHUNBANG Biotechnology Co., Ltd Address before: 210000 Phoenix Plaza, No. 1 Hunan Road, Gulou District, Nanjing City, Jiangsu Province Patentee before: Li Shulan |
|
TR01 | Transfer of patent right |